| Literature DB >> 21139713 |
Somenath Kundu1, Subhra Mitra, Subhasis Mukherjee, Soumya Das.
Abstract
BACKGROUND: Thoracic empyema is a disease of significant morbidity and mortality, especially in the developing world where tuberculosis remains a common cause. Clinical outcomes in tuberculous empyema are complicated by the presence of concomitant fibrocavitary parenchymal disease and frequent bronchopleural fistulae. We performed a prospective study over a one-and-a-half-year period with the objective of comparing the clinical profiles and outcomes of patients with tuberculous and nontuberculous empyema.Entities:
Keywords: Bronchopleural fistula; empyema; parapneumonic effusion; tuberculous empyema
Year: 2010 PMID: 21139713 PMCID: PMC2988167 DOI: 10.4103/0970-2113.71939
Source DB: PubMed Journal: Lung India ISSN: 0970-2113
Comparison of clinical characteristics – tuberculous vs. nontuberculous empyema
| Tuberculous empyema ( | Nontuberculous empyema ( | ||
|---|---|---|---|
| Age in years mean [SD] (range) | 32.7 [8.45], (14–65) | 46.5 [15.38] (13–72) | |
| Duration of Illness more than 1 month | 24 (82.8) [171.2 days, 1–24 months] | 13 (28.3) [20 days, 5 days to 3 months] | 0.0001 |
| Cough | 24 (82.8) | 38 (82.6) | 0.76 |
| Fever | 22 (75.5) | 46 (100) | 0.04 |
| Shortness of breath | 27 (93.1) | 46 (100) | 0.05 |
| Hemoptysis | 7 (24.3) | 3 (6.5) | 0.05 |
| Empyema necessitans | 5 (17.2) | 0 | |
| Bronchopleural fistula (BPF) | 14 (48.8) | 5 (10.9) | 0.0004 |
P<0.05; Figures in parenthesis are in percentage
Comorbid conditions
| Comorbidities | Tuberculous empyema ( | Nontuberculous empyema ( | Total ( |
|---|---|---|---|
| Diabetes mellitus | 10 (34.5) | 13 (28.3) | 23 (30.7) |
| Alcoholism | 1 | 8 | 9 (12) |
| HIV positive | 1 | 1 | 2 (2.7) |
| Seizure disorder | 0 | 2 | 2 (2.7) |
| Cancer/chemotherapy | 0 | 3 | 3 (4) |
| Liver abscess | 0 | 2 | 2 (2.7) |
| Prolonged steroid use | 0 | 1 | 1 (1.3) |
Figures in parenthesis are in percentage
Figure 1Chest X-ray showing right-sided pyopneumothorax with bilateral parenchymal lesions
Diagnosis of tuberculous empyema (n = 29)
| AFB-positive pleural fluid smear | 27 (93.1) |
| AFB-positive sputum smear | 19 (65.5) |
| Parenchymal consolidation/cavity in CXR/CT | 20 (68.9) |
Figures in parenthesis are in percentage
Bacteria isolated in pleural fluid culture of nontuberculous empyema patients (n = 22)
| Organism | Number (%) |
|---|---|
| Gram-positive bacteria | |
| Staphylococcus aureus | 11 (50) |
| Streptococcus haemoliticus | 1 |
| Gram-negative bacteria | 10 (45.5) |
| 3 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 |
Drainage modalities
| Tuberculous empyema ( | Nontuberculous empyema ( | |
|---|---|---|
| USG-guided aspiration | 5 (17.2) | 9 (19.6) |
| Pigtail catheter drainage | None | 4 (8.7) |
| ICTD | 24 (82.88) | 33 (71.7) |
| Surgical drainage | 16 (55.2) | 5 (10.9) |
P value<0.0001; Figures in parenthesis are in percentage
Figure 2Peroperative photograph during decortication showing air bubbles from bronchopleural fistula
Figure 3Chest X ray after thoracoplasty
Treatment modalities and outcome – tuberculous vs. nontuberculous empyema
| Tuberculous empyema ( | Nontuberculous empyema ( | ||
|---|---|---|---|
| Mean duration of ICTD [range] | 48.7 days [10–135 days] | 23.2 days [6–67 days] | |
| ICTD > 1 month | 17 (70.8) | 9 (24.3) | 0.04 |
| Surgical drainage | 16 (55.2) | 5 (10.9) | 0.0001 |
| Failure of lung re-expansion after surgery | 4 (13.8) | None | |
| Death | 1 (3.4) | None |
P value<0.05; Figures in parenthesis are in percentage